Srinivas Akkaraju - May 21, 2025 Form 4 Insider Report for ALUMIS INC. (ALMS)

Role
Director
Signature
/s/ Srinivas Akkaraju
Stock symbol
ALMS
Transactions as of
May 21, 2025
Transactions value $
$0
Form type
4
Date filed
5/23/2025, 08:47 PM
Previous filing
May 6, 2025
Next filing
May 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
AKKARAJU SRINIVAS Director C/O ALUMIS INC., 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO /s/ Srinivas Akkaraju 2025-05-23 0001253170

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALMS Common Stock Award +1.21M +33.86% 4.8M May 21, 2025 By Samsara BioCapital, L.P. F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 21, 2025, pursuant to the Agreement and Plan of Merger, dated as of February 6, 2025 and amended on April 21, 2025, by and among the Issuer, ACELYRIN, Inc. ("ACELYRIN"), and Arrow Merger Sub, Inc., a direct wholly owned subsidiary of the Issuer ("Merger Sub"), Merger Sub merged with and into ACELYRIN with ACELYRIN continuing as the surviving corporation and as a wholly owned subsidiary of the Issuer (the "Merger"). Each share of ACELYRIN common stock was exchanged for 0.4814 shares of the Issuer's common stock.
F2 Received in exchange for 2,523,022 shares of common stock of ACELYRIN in connection with the Merger (as described in footnote 1) on May 21, 2025.
F3 Shares are held directly by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara GP") is the general partner of Samsara LP. The Reporting Person, as the managing member of Samsara GP, shares voting and investment authority over the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.